Our compendium of microenvironmental gene and protein profiles provides insights into the immuno-biology of AML and could inform the delivery of personalized immunotherapies to IFN-γ-dominant AML subtypes.Ĭopyright © 2020 The Authors, some rights reserved exclusive licensee American Association for the Advancement of Science. Interferon (IFN)-γ-related mRNA profiles were predictive for both chemotherapy resistance and response of primary refractory/relapsed AML to flotetuzumab immunotherapy. Using 442 primary bone marrow samples from three independent cohorts of children and adults with AML, we defined immune-infiltrated and immune-depleted disease classes and revealed critical differences in immune gene expression across age groups and molecular disease subtypes. This study dissected the complexity of the immune architecture of AML at high resolution and assessed its influence on therapeutic response. Although immunotherapy may be an attractive modality to exploit in patients with AML, the ability to predict the groups of patients and the types of cancer that will respond to immune targeting remains limited. myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. 13 John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK.12 Division of Oncology, Department of Internal Medicine, Washington University in St.11 Department of Hematology, Erasmus University Medical Centre, 3000CA Rotterdam, Netherlands.10 Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham NG11 8NS, UK.9 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.8 National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany.7 Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.6 MacroGenics Inc., Rockville, MD 20850, USA. ![]() 5 Department of Pediatrics, Division of Oncology and Centre for Childhood Cancer Research, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, PA 19104, USA.4 Department of Medicine, Universitätsklinikum Carl Gustav Carus, 01307 Dresden, Germany.3 NanoString Technologies Inc., Seattle, WA 98109, USA.2 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.1 John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham NG11 8NS, UK.
0 Comments
Leave a Reply. |